Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. - Wikidata - awgldk - TriplyDB

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

http://www.wikidata.org/entity/Q33691838

about

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Oncolytic virotherapy for human malignant mesothelioma: recent advances Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer Understanding and altering cell tropism of vesicular stomatitis virus Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1 What's the place of immunotherapy in malignant mesothelioma treatments?Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.Pharmacologic activation of the innate immune system to prevent respiratory viral infections.Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.Curative one-shot systemic virotherapy in murine myeloma.Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1 Regulating cytokine function enhances safety and activity of genetic cancer therapies Vesicular stomatitis virus as a treatment for colorectal cancer Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.Translational advances in pleural malignancies.Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Oncolytic vaccines.Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma.Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.Vesiculovirus neutralization by natural IgM and complement.Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.Oncolytic Viral Therapy for Mesothelioma.Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Model-based rational design of an oncolytic virus with improved therapeutic potential.Review: Oncolytic virotherapy, updates and future directions.Tumor Restrictions to Oncolytic Virus.

P2860

Q26775030-3857E8AC-5D7E-4604-963A-13B0B7314F77 Q26826590-CC357D5A-33F1-4A4D-BA86-281357A020E5 Q27021839-FC4E751C-AD38-4F53-B7E5-B81D67F255F1 Q27687067-D6C562F7-2241-4EE7-95E5-5C0AB19D955A Q33579385-A6EF12FA-CD61-43C3-8B29-1F4D169E15E2 Q33579883-6EEA2920-55AC-4520-A7BE-EF8FB16E04FD Q33781142-3110BCD0-2857-4DE5-B953-128E314DA13D Q35275179-8676AEAD-F1DD-469C-AA12-A0A1C30161A0 Q35575688-D6A1ED56-249F-447B-8BF5-DEBD944A6399 Q35692082-23063A3A-B194-4AFA-B969-F8BB4BF53840 Q35861186-E4700115-B575-496F-8DEF-718791918047 Q35876239-57099BD8-C1F5-4C4B-BA76-B40305AED106 Q36139716-24D4D608-E78A-4935-8790-0B1A19D3331A Q36202610-921274F7-6F34-41B3-92E4-3F3B3EC27EF0 Q36512561-CFDC3858-29F6-4BA1-8ECB-AA6D9DD8A352 Q36928614-AA6F6AB5-306F-4668-BC99-A22D87CF91E8 Q37076976-F1A43610-0ABC-466D-A24C-960267625CD5 Q37292354-D85A0B64-2A67-46D5-8016-FF360B9C18C8 Q37373616-3F66F1B4-03BE-4BC4-9525-63B2CBEDADD9 Q37381298-02E2E90D-500D-43D9-87A4-7FA4A016768B Q37646792-E5CAA959-BC32-45FA-957E-9DE6E64ABC08 Q37806309-C4353940-8A33-47C1-8200-426F56C10B8C Q37933439-508BE2F0-0D46-46CE-857C-FF08F5FF39AB Q38025696-2D7132EC-FA9A-404D-8AEB-C5D774D7981D Q38152474-A3F100B4-E11E-441F-AA40-F864F8D9595B Q38209337-DE7E1F78-9321-4472-B282-004275D13D6B Q38860227-DF74D87D-AD41-4E5A-AA33-AB8AE61BEFE8 Q38955561-7C5E2BA8-A270-44B2-AB26-539E7E224A77 Q39005715-3CCF91D2-AA5D-4BFF-B343-74E512BC3D1E Q39013686-E2CA72F5-CF12-4D6F-B1CB-D904A9464F4A Q39127778-55B96A87-369E-44F1-A4AB-9D56C8B63357 Q39224943-F6B08F5D-C8C3-43C1-8002-AEDA55F80156 Q39413447-8590DFE8-BF7D-4193-A011-E04C87D554B1 Q39427565-ACE43B92-A071-4C37-9E9E-45F74EA26E2C Q39788723-9E31EE29-4395-4BC7-A697-C3F1FAA89DF1 Q40051845-DD754B80-2B4F-45B9-BEC5-89D0F508D8A0 Q42378527-D8C50C24-CAD3-46D2-8BE9-914ABABAA460 Q45350759-1B316B10-8F9E-4E50-86FE-881AC01A92B2 Q47160989-C3E14DE0-BC51-4BB2-85A0-26193D2C0C20 Q51846287-53D16555-C782-4C83-B959-8DC527CC5C74

P2860

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

http://www.wikidata.org/entity/Q33691838

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Evaluation of an attenuated ve ...... ss defines potential efficacy.

@ast

Evaluation of an attenuated ve ...... ss defines potential efficacy.

@en

type

label

Evaluation of an attenuated ve ...... ss defines potential efficacy.

@ast

Evaluation of an attenuated ve ...... ss defines potential efficacy.

@en

prefLabel

Evaluation of an attenuated ve ...... ss defines potential efficacy.

@ast

Evaluation of an attenuated ve ...... ss defines potential efficacy.

@en

P1433

Q33691838-B406F576-5B6A-478B-AAB0-36AE10EF6046

P1476

Q33691838-1DA5EBED-0102-48AE-9C31-1F58ABE230EC

P2093

Q33691838-043575AA-D197-482E-B334-D38D9F656607

Q33691838-0DF9F214-F4BB-4750-8C46-8CD3DAD25ADC

Q33691838-27B7190F-FEF5-4AEE-B9EA-7DC073713E03

Q33691838-380ED0D7-AA03-4102-BEB2-09279FCEBD36

Q33691838-529F5E9D-879F-49EA-9795-753AE6A07896

Q33691838-67FA2F1A-2022-4890-82C9-48A5291DB9FC

Q33691838-8DB89D7E-CB1F-4122-84FB-6343A3D94AD6

Q33691838-A435F92B-30FE-48CD-9C42-1E6F324342F5

Q33691838-A525838E-82F8-4886-8432-3EBC59FF5DEE

Q33691838-BB0C36A1-2294-46AA-8FB6-E8F809E7C800

P2860

Q33691838-060BA549-9AEF-4CE3-821C-E622EA3F1D46

Q33691838-08998954-22DC-4EF5-B274-51F85F319F01

Q33691838-0A4CF70D-AF28-4D0A-965C-3752E9FB1C48

Q33691838-0C74BDA9-8ACD-4EB1-870B-F912486031C3

Q33691838-0EA3C7EE-790D-428C-BC53-973A7F15C353

Q33691838-1980EABF-665A-4D3F-A7F3-630289814925

Q33691838-21704916-8E7B-4619-95E9-18364EE762D2

Q33691838-2D5B3789-70FF-430D-8A92-840F486F7806

Q33691838-30C7A80B-9CDD-452A-8DE9-B4385C7ECBB5

Q33691838-3BC7FD45-2B64-4908-A4D3-23FFE5692758

P304

Q33691838-C0F71999-9356-487E-95E4-30495C224BDF

P31

Q33691838-12C3F8A5-126C-45FE-8546-9878D31EC366

P356

Q33691838-BE20F604-5259-47F7-ACF5-00F07B5358C2

P433

Q33691838-A0732972-41A8-4D5F-8A9F-35FFEAD68ECF

P478

Q33691838-5EA17D2A-FF1D-4C1D-86B7-F95F8D51AA4C

P50

Q33691838-7B6E46B1-C051-4206-ACD7-2B7AF2492FFC

P577

Q33691838-1F60D5CA-BB1A-4D4E-9FF6-813D52D31EBF

P5875

Q33691838-9047E7AB-8D42-4C20-84AB-7EA0EE0750C7

P698

Q33691838-86E35A3F-24A7-49BB-B9DF-5738B6D6153B

P921

Q33691838-AE9B9C26-122E-4EDD-92C8-6BE4094158C3

P932

Q33691838-C228DAF7-CD02-45A7-8AB1-95FE7BD38A45

P356

P1433

Human Gene Therapy

P1476

Evaluation of an attenuated ve ...... ss defines potential efficacy.

@en

P2093

Atsushi Okumura

http://www.w3.org/2001/XMLSchema#string

Daniel H Sterman

http://www.w3.org/2001/XMLSchema#string

Glen N Barber

http://www.w3.org/2001/XMLSchema#string

Guanjun Cheng

http://www.w3.org/2001/XMLSchema#string

Jing Sun

http://www.w3.org/2001/XMLSchema#string

Leslie Litzky

http://www.w3.org/2001/XMLSchema#string

Liang-Chuan S Wang

http://www.w3.org/2001/XMLSchema#string

Mark J Federspiel

http://www.w3.org/2001/XMLSchema#string

Richard G Vile

http://www.w3.org/2001/XMLSchema#string

Ronald N Harty

http://www.w3.org/2001/XMLSchema#string

P2860

Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo

Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.

Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.

IFNs and STATs in innate immunity to microorganisms.

RNA viruses as virotherapy agents.

Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.

Vesicular stomatitis virus: re-inventing the bullet.

P304

51-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2009.088

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Stephen J Russell

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26775230

http://www.w3.org/2001/XMLSchema#string

P698

19715403

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

2829454

http://www.w3.org/2001/XMLSchema#string